Correction to “Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma”

David A. Sandham; Lucy Barker; Lyndon Brown; Zarin Brown; David Budd; Steven J. Charlton; Devnandan Chatterjee; Brian Cox; Gerald Dubois; Nicholas Duggan; Edward Hall; Julia Hatto; Catherine Leblanc; Janet Maas; Jodie Manini; Rachael Profit; Darren Riddy; Catherine Ritchie; Bindi Sohal; Duncan Shaw; Rowan Stringer; David A. Sykes; Matthew Thomas; Katharine L. Turner; Simon J. Watson; Ryan West; Elisabeth Willard; Gareth Williams; Jennifer Willis

首页> 外文期刊>ACS medicinal chemistry letters >Correction to “Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP₂ Receptor Antagonist for Treatment of Asthma”

【24h】

Correction to “Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP₂ Receptor Antagonist for Treatment of Asthma”

机译：校正“Fevipiprant（NVP-QAW039）的发现，有效和选择性DP _{2 受体拮抗剂用于治疗哮喘”}

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《ACS medicinal chemistry letters》 |2017年第9期|共1页
作者
David A. Sandham; Lucy Barker; Lyndon Brown; Zarin Brown; David Budd; Steven J. Charlton; Devnandan Chatterjee; Brian Cox; Gerald Dubois; Nicholas Duggan; Edward Hall; Julia Hatto; Catherine Leblanc; Janet Maas; Jodie Manini; Rachael Profit; Darren Riddy; Catherine Ritchie; Bindi Sohal; Duncan Shaw; Rowan Stringer; David A. Sykes; Matthew Thomas; Katharine L. Turner; Simon J. Watson; Ryan West; Elisabeth Willard; Gareth Williams; Jennifer Willis;
展开▼
作者单位

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

Novartis Institutes for Biomedical Research Horsham Research Centre Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;化学;
关键词

相似文献

外文文献
中文文献
专利

1. Correction to “Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP₂ Receptor Antagonist for Treatment of Asthma” [J] . David A. Sandham, Lucy Barker, Lyndon Brown, ACS medicinal chemistry letters . 2017,第9期

机译：校正“Fevipiprant（NVP-QAW039）的发现，有效和选择性DP _{2 受体拮抗剂用于治疗哮喘”}
2. FEVIPIPRANT, A POTENT SELECTIVE PROSTAGLANDIN D2 RECEPTOR 2 (DP2) ANTAGONIST, DOSE-DEPENDENTLY INHIBITS PULMONARY INFLAMMATION IN A MOUSE MODEL OF ASTHMA [J] . Sandham D., Asano K., Erpenbeck V, Respirology : . 2019,第S1期

机译：Fevipiprant，一种有效的选择性前列腺素D2受体2（DP2）拮抗剂，剂量依赖性地抑制哮喘小鼠模型中的肺炎症
3. Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases [J] . Crosignani S., Prêtre A., Jorand-Lebrun C., Journal of Medicinal Chemistry . 2011,第20期

机译：发现有效，选择性和口服可生物利用的炔基苯氧基乙酸CRTH2（DP2）受体拮抗剂，用于治疗过敏性炎症疾病
4. Potent and selective peptide agonist/antagonist analogues at human melanocortin receptor-4 [C] . Minying Cai, Paolo Grieco, Dev Trivedi, European Peptide Symposium . 2002

机译：有效和选择性肽激动剂/拮抗剂类似物在人黑色主义素受体-4
5. Addition of leukotriene receptor antagonists versus long acting beta agonists to inhaled corticosteroid therapy for asthma treatment in older adults: A retrospective data analysis of effectiveness, safety and cost. [D] . Altawalbeh, Shoroq Mahmoud. 2015

机译：在吸入性糖皮质激素治疗中，将白三烯受体拮抗剂与长效β激动剂相比，用于老年人的哮喘治疗：有效性，安全性和成本的回顾性数据分析。
6. Correction to Discovery of Fevipiprant (NVP-QAW039)a Potent and Selective DP2 Receptor Antagonist for Treatmentof Asthma [O] . David A. Sandham, *, Lucy Barker, 2017

机译：更正为发现夫芬普兰（NVP-QAW039）高效选择性的DP2受体拮抗剂治疗哮喘
7. Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthma [O] . Sandham, David A., Barker, Lucy, Brown, Lyndon, 2017

机译：发现氟维西平（NVP-QAW039），一种有效的选择性DP2受体拮抗剂，可治疗哮喘

Correction to “Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma”

著录项

相似文献

相关主题

期刊订阅

Correction to “Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP₂ Receptor Antagonist for Treatment of Asthma”